Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
DB-727
- Development stage
- Preclinical
- Lead developer
- Zhejiang Daozhijian Biotechnology
- Modality
- Fc-Fusion Proteins → Carrier/Scaffold Proteins → Recombinant Proteins and Enzymes
01
Overview
DB-727 is a preclinical-stage, bifunctional fusion protein consisting of a bivalent anti-programmed cell death protein 1 (PD-1) antibody fused to a modified interleukin-2 (IL-2) cytokine. Developed by TrueSimple Bio, DB-727 is designed to target and activate tumor-infiltrating PD-1-positive T cells. The molecule utilizes an IL-2 receptor subunit alpha (IL-2Rα)-biased modification strategy, retaining high affinity for IL-2Rα to selectively stimulate effector T cells while minimizing systemic toxicity. By combining PD-1 checkpoint blockade with localized IL-2 receptor agonism, DB-727 aims to enhance anti-tumor immune responses in solid tumors.
02
Targets
IL2RA (Interleukin-2 receptor alpha subunit)PDCD1 (Programmed cell death protein 1 receptor)
Beyond the preview
Go deeper on DB-727.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on DB-727.